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Topical Cidofovir Is More Effective than Is Parenteral
Therapy for Treatment of Progressive Vaccinia
in Immunocompromised Mice
Donald F. Smee, Kevin W. Bailey, Min-Hui Wong, Miles K. Wandersee, and Robert W. Sidwell
Department of Animal, Dairy, and Veterinary Sciences, Institute for Antiviral Research, Utah State University, Logan

Background. Severe complications may arise as a result of virus dissemination after smallpox (live vaccinia
virus) vaccination, particularly in immunocompromised individuals. We developed a new mouse model for studying
the effects of antiviral agents on progressive vaccinia virus infections.
Methods. Hairless mice were treated with cyclophosphamide (100 mg/kg/day) every 4 days starting 1 day
before vaccinia virus exposure to wounded skin. Primary lesions progressed in severity, satellite lesions developed,
and the infection eventually killed the mice.
Results. Topical treatment with 1%-cidofovir cream (twice daily for 7 days) was much more effective in
reducing the severity of primary lesions and the number of satellite lesions than was parenteral cidofovir treatment
(100 mg/kg/day, given every 3 days). Both forms of treatment delayed death. Topical drug treatment markedly
reduced virus titers in the skin and snout, whereas parenteral treatment did not, suggesting that the latter treatment
resulted in lower drug exposure to skin. Topical treatment starting 9 days after infection delayed death by 10 days,
compared with treatment with placebo. Combining topical and parenteral cidofovir treatments provided the greatest
reduction in lesion severity and prolongation of life.
Conclusions. Topical cidofovir treatment was superior to parenteral treatment. This new animal model may
be useful in evaluation of the efficacy of treatment regimens against complications from smallpox vaccination.
Historically, immunization against smallpox (variola) virus infection was accomplished by use of certain strains
of cowpox or vaccinia virus or (with much greater risk)
by skin scarification with variola virus itself [1]. The
smallpox vaccination, when given intradermally on the
upper arm, generally remains localized, producing small
pustules that become confluent, forming a large vesicle.
The vesicle eventually scabs over and falls off [2]. Occasionally, complications may arise following smallpox
vaccination. These may include dissemination of the
infection to other sites on the body (such as other areas
of the skin or the eyes), progressive vaccinia, eczema
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vaccinatum, and/or generalized vaccinia virus infection
[3]. Fetal infection also has been known to occur. Bacterial superinfection of the vaccination site is the most
common nonviral complication. Many of the more serious viral conditions are the result of the individual
being in an immunosuppressed state, owing to genetic
immunodeficiency, age, or chemotherapy [3].
The threat of smallpox has reemerged, owing to the
potential use of variola virus as a biological weapon in
bioterrorism [4, 5]. Thus, although smallpox vaccination ceased as a common practice around 1980, the
practice has been escalated in response to this perceived threat, which opens the door for new cases of
serious vaccination complications. Compared with that
in 1980, the present population has a larger number of
immunosuppressed individuals, owing to HIV infection
and AIDS, an increase in organ transplantations, and
chemotherapy. Modern medicinal chemistry has produced small molecules, such as cidofovir [6, 7], cidofovir prodrugs [8, 9], and 2-amino-7-([1,3-dihydroxy2-propoxy]methyl)purine [10, 11], that may be able to
effectively treat such infections. However, the animal

models that have been employed in the past to study antiviral
treatments have not mimicked well many of the progressive vaccinia conditions described above. The majority of the models
have been developed using normal animals. Lethal infections
have been induced by intranasal inoculation of vaccinia or cowpox viruses [6, 7]. Other antiviral studies have focused on nonlethal infections of the skin, tails, or eyes of animals [12]. Some
studies have used severe combined immunodeficient (SCID)
mice infected parenterally or intranasally [13, 14]. One report
indicated that SCID mice infected intradermally on the tail develop progressively worse tail lesions and later die from a systemic
infection and that cidofovir combined with vaccinia immune
globulin (VIG) was beneficial in treatment [15].
Over the years, we have studied infections in mice that have
been immunosuppressed using repeated cyclophosphamide injections. We found that, with either murine cytomegalovirus
(MCMV) or murine gamma herpesvirus 68, the infections progressed and the animals died [16, 17]. The use of cyclophosphamide for such studies was originally reported by Selgrade et
al. [18], who studied MCMV infections in mice. Because cyclophosphamide-induced immunosuppression is not permanent,
the mice have to be treated every few days to maintain a profound
immunosuppressed state. In this condition, the animals responded to MCMV infection in a manner similar to SCID mice
[19]. Worthington et al. [20] showed that mice treated with
cyclophosphamide died from an otherwise nonlethal vaccinia
virus infection induced by intracutaneous virus inoculation.
Treatment of the animals with antibody prevented death.
We wanted to develop a model in which exposed skin could
be infected with vaccinia virus, progressive lesion development
would ensue, and viral dissemination to other areas of the skin
would occur. Hairless animals were targeted, to avoid problems
associated with frequent depilation. Two strains of hairless mice
are readily available, athymic nude (T cell immunodeficient)
and normal hairless mice. In addition, there are normal hairless
rats and hairless guinea pigs commercially available. A number
of vaccinia virus strains exist that could be used for infection.
In our preliminary studies, we found that athymic nude mice
infected with the IHD, Lederle, and WR strains of vaccinia
virus developed lesions; however, the lesions did not continue
to get progressively larger beyond a certain size, and few satellite
lesions appeared before the mice died from systemic infection
(authors’ unpublished data). In the same studies, normal hairless mice developed lesions that quickly resolved, and the mice
recovered fully from the infections. Hairless mice immunosuppressed with cyclophosphamide developed disseminated disease
when infected with the WR strain of vaccinia virus and later
died. Lesser degrees of severity were seen with infection with the
IHD and Lederle strains of vaccinia virus. With these initial
findings, we began studying the effects of cidofovir treatment,
administered topically and/or parenterally, on vaccinia virus (WR

strain) cutaneous infections in immunosuppressed hairless mice.
This report describes the results of these experiments.
MATERIALS AND METHODS
Mice. Female, specific pathogen–free, SKH-1 hairless mice
(∼24 g), 7–8 weeks old, were obtained from Charles River Labs.
The mice were quarantined 48 h before use and were maintained
on Teklad Rodent Diet (Harlan Teklad) and tap water at the
Laboratory Animal Research Center of Utah State University
(Logan), which is accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care International.
Large numbers of these mice were not available from the supplier;
thus, generally 7–8 mice were used per group (held until death),
depending on the total number required for each experiment.
Virus. Vaccinia virus (WR strain) was purchased from the
American Type Culture Collection. The virus was propagated in
African green monkey kidney (MA-104; Cambrex Bio Science)
cells for use in these studies.
Compound. Cidofovir was provided by Mick Hitchcock of
Gilead Sciences. Dermovan (Owen Laboratories) was purchased
from a local pharmacy for preparation of the topical cidofovir
cream [21]. Cidofovir was dissolved in water at a concentration
of 25 mg/mL and then combined with Dermovan to prepare the
1%-cidofovir cream formulation. Dermovan combined with water served as the placebo control. Saline was used to dissolve
cidofovir (100 mg/kg/day) for intraperitoneal (ip) injection. Saline served as the placebo control for ip treatments.
Experiment design. Mice were anesthetized with ketamine
(100 mg/kg) by ip injection. They were scratched sufficiently
to penetrate the dermal layer in the hip and shoulder areas on
1 side of the body. The area of each scratched site was ∼25
mm2 (5 mm ⫻ 5 mm) and consisted of 4–5 scratches in 1
direction. A 25-mL volume of vaccinia virus (containing ∼2.5
⫻ 105 pfu) was placed on each wound area and remained there
while the mice rested under the influence of the anesthesia.
Immunosuppression was accomplished by ip treatment of the
mice with cyclophosphamide (100 mg/kg/day) every 4 days,
starting 1 day before virus challenge, until all the mice died.
Creams (∼50–100 mL) were applied with a spatula to each lesion
site twice daily for 7 days, starting at different times after virus
challenge. As they formed, satellite lesions were treated in a
similar manner. Cidofovir was administered by ip injection
every 3 days, starting at different times after virus challenge,
through day 21.
Three parameters were used to evaluate disease progression.
(1) Deaths were recorded daily for as long as the mice survived,
which was !40 days in these experiments. We treated uninfected
hairless mice with cyclophosphamide for up to 45 days, and the
mice remained healthy. (2) The primary lesion area was measured
in square millimeters (length times width). Satellite lesions that
merged with the primary lesion were not included in the mea-
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surement of the primary lesion area. (3) The number of satellite
lesions per mouse was counted each day. Satellite lesions could
occur anywhere on the body. Mice were tagged by toe clipping
and were accounted for individually. Their final scores for primary lesion area and number of satellite lesions were maintained,
for counting purposes, through day 21 of the experiment.
Virus titration from infected tissues. Determinations of
virus titers were made from tissues obtained on different days
after infection. Homogenization and plaque-assay titrations
were performed as described elsewhere [7].
Statistical evaluation. The 2-tailed Fisher’s exact test was
used to evaluate increases in number of survivors. The 2-tailed
Mann-Whitney U test was used to analyze differences in the
mean number of days until death, reductions in primary lesion
area, reductions in number of satellite lesions, and differences
in virus titers in tissue.
RESULTS
Development of animal model. Experiments were initially
conducted using normal hairless mice infected on the skin with
vaccinia virus. In those studies, the mice developed self-limiting
primary lesions that peaked in severity around days 5–7 after
infection. High virus titers (up to 108 pfu/g) were detected in
skin tissues. The lesions quickly healed after that time and did
not disseminate. None of the mice died during infection. A
pilot antiviral study was conducted using normal mice and ip
cidofovir treatment on days 1 and 4 after virus challenge. In
that experiment, the peak in severity of virus lesions occurred
on day 5 after infection. On that day, the mean size of the
lesion area for the cidofovir-treated group was 26  12 mm2,
compared with 57  26 mm2 for the placebo-treated group,
and virus titers in skin lesions of the cidofovir-treated and
placebo-treated groups were 8.6  0.4 and 8.8  0.2 log10 pfu/
mL, respectively. Thus, parenteral cidofovir treatment had minimal effect on the infection. Because of the short duration of
this self-limiting infection in normal mice, we did not pursue
other forms of antiviral treatment or conduct in-depth studies.
Instead, we began investigating ways to prolong the infection and
to enhance its severity, which led to studying the effect of immunosuppression (particularly by means of cyclophosphamide)
on the severity of the vaccinia virus (WR strain) infection.
When the mice were treated every 4 days with cyclophosphamide, to induce immunosuppression, a different pattern of
infection emerged than that seen in normal mice. Primary lesions became progressively larger over time, and many satellite
lesions formed during the late stage of the infection, before
death. Figure 1 shows these immunosuppressed mice on different days after infection. On day 5, swelling was evident under
the skin of the infection sites located on the hip and shoulder
regions, but a full breakout of the lesion had not yet occurred
(figure 1A). By day 9, poxlike vesicles were fully formed, but
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no satellite lesions were evident (figure 1B). By day 18, numerous satellite lesions had developed, and the primary lesions
were more severe. In figure 1C, satellite lesions appear to be
clustered mostly around the primary lesion area. Numerous
disseminated satellite lesions had developed (figure 1D), including many on the abdominal surface (not visible in photograph). The front paw also was swollen in this mouse. Swelling of ⭓1 paw may occur in either the front or the hind limbs
and on either side of the body. Many mice developed lesions
around the mouth, probably as a result of rubbing and/or chewing the primary lesion area. Because the mice were immunosuppressed, they ultimately died from the infection. By day 18
(figure 1C and 1D), the mice had started to lose weight and
had become sedentary in their behavior. They died within a
few days after the photographs were taken.
Development of virus titers was determined in the mice after
cutaneous infection (figure 2). Virus titers developed very rapidly in the skin, reaching and persisting at concentrations 1108
pfu/g. Later, the mice developed high virus titers in their snouts,
which is believed to have been due to transmission of infection
from the primary lesion area as a result of the mice rubbing
the lesions with their snouts. The lesions began to irritate the
mice, and the mice reacted by scratching them with their paws
and biting them. Virus titers progressively increased in the lungs
over time, which may represent a progression of infection from
snout to lungs by means of inhalation. The virus infection eventually underwent dissemination to the other visceral organs and
the brain.
Topical and ip cidofovir treatment. Studies were conducted to determine the efficacy of cidofovir against vaccinia
virus cutaneous infections in immunosuppressed mice when
treatment began 1 day after infection. Topical treatments given
twice daily for a week were compared with ip treatments given
every 3 days through day 21 after infection (figure 3). The iptreatment regimen was similar to that found to be effective
against a cowpox virus respiratory infection in SCID mice [6].
Both the topical and the ip treatments significantly delayed the
time to death (P ! .001), compared with time to death in the
placebo-treated groups (figure 3A). Parenteral cidofovir treatment was less effective in reducing primary lesion areas (figure
3B) and numbers of satellite lesions (figure 3C) than was topical
application. However, both treatments caused significant reductions in lesion severity, compared with lesion severity in the
placebo-treated groups. As part of the experiment, virus titers
in various tissues were determined on day 14 after infection
(figure 4). Topical treatment caused dramatic reductions in
virus titers in the skin and snout. A lesser but statistically significant effect was seen for virus titers in the liver. In contrast,
ip treatment had little, if any, effect in reducing virus titers in
the skin and snout. However, reductions in virus titers in the
lungs, kidney, and liver were seen with ip treatments.

Figure 1. Vaccinia virus (WR strain) lesion development on the backs of immunosuppressed mice at 5 (A), 9 (B), and 18 (C and D) days after virus
exposure. The animals were initially infected in the hip and shoulder areas. The day-18 photographs illustrate different patterns of satellite-lesion
dissemination.

Effects of delayed cidofovir treatment. The effect of starting cidofovir treatment at different times after infection was
studied next. Topical and ip treatments began 1, 3, or 5 days
after infection and continued for a total of 7 days (topical) or
through day 21 (ip) (figure 5). Results of topical treatments
starting on day 1 were similar to those shown in figure 3, with
regard to impact on survival, scores for primary lesion area,
and numbers of satellite lesions. Parenteral treatment was not
as effective in delaying the time to death as was topical treatment (figure 5A). In 2 additional studies in which treatment
started 1 day after infection, topical treatment also was more
effective in delaying death than was ip treatment (data not
shown). Treatments by the ip route reduced scores for primary
lesion area and numbers of satellite lesions significantly, but
the overall effect was not as good as that of topical treatment
(figure 5B and 5C). A delay in the start of treatment until day
3 or 5 resulted in reduced efficacy, but significant reductions
in parameters for lesion severity were still seen. Topical treatments started on day 3 were not as effective in delaying death
as those started on day 1. Parenteral treatments started on day
1, 3, or 5 were similarly effective in delaying death.
Topical cidofovir treatment starting on day 9. Primary
skin lesions were well formed by day 9 after infection (figure
1B), before initiation of treatment. The impact of cidofovir on
this type of infection was studied by using 3%- and 1%-cidofovir topical cream, compared with placebo cream. Treatments
were given twice daily for 7 days. Mean (SD) time until death
for the 3 treatment groups (n p 8 for each group) was
22.5  4.9 (P ! .01), 20.3  3.5 (P ! .01), and 14.6  2.3 days,

respectively. Because the primary lesions were large before the
start of treatment, no reductions in lesion size were seen. On
day 17 after infection, the mean (SE) number of satellite
lesions per mouse was 14.1  2.2, 25.0  3.2, and 23.0  3.0
lesions, respectively. Because of mouse-to-mouse variability in
the number of satellite lesions, the results for the 3% cidofovir–
treated group, compared with the placebo-treated group, were
not statistically significant.
Combination of topical and ip treatments. Topical and

Figure 2. Virus titers in various tissues of female immunosuppressed
hairless mice during cutaneous infection with vaccinia virus (WR strain).
Mice were immunosuppressed by intraperitoneal treatments with cyclophosphamide (100 mg/kg/day) every 4 days, starting 1 day before infection. Data are mean + SE (n p 3, except for day 19 [n p 1]).
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Figure 3. Efficacies of topical and intraperitoneal (ip) cidofovir treatments when started 1 day after infection of immunosuppressed hairless mice
with vaccinia virus (WR strain). Topical treatments were given twice daily for 7 days, and parenteral treatments were administered once daily every
3 days, ending on day 19 after infection. Data are mean + SE (n p 8 ). A, Percent survival; B, mean size of primary lesion area (in square millimeters);
C, mean number of satellite lesions. *P ! .05; **P ! .01; ***P ! .001.

ip treatments both had an impact on reduction of mortality in
the model, although topical treatments were superior in reducing parameters of lesion severity. A study was conducted
to determine whether the combination of topical and ip treat-

ments would be more effective than either treatment alone,
when treatment started 5 days after infection. For this study,
groups consisted of 8–10 mice. Mice treated topically with 1%cidofovir cream for 1 week lived a mean (SD) of 19.8  3.2

Figure 4. Virus titers in various tissues of immunosuppressed hairless mice on day 14 after cutaneous infection with vaccinia virus (WR strain).
Topical treatments were given twice daily for 7 days, starting on day 1 after infection. Intraperitoneal (ip) treatments were administered once daily
every 3 days, starting on day 1 and ending on day 19 after infection. Data are mean + SE (n p 5). **P ! .01; ***P ! .001.

1136 • JID 2004:190 (15 September) • Smee et al.

Figure 5. Efficacies of topical and intraperitoneal (ip) cidofovir treatments when started 1, 3, or 5 days after infection of immunosuppressed hairless
mice with vaccinia virus (WR strain). Topical treatments were given twice daily for 7 days, and ip treatments were administered once daily every 3
days, ending on or before day 21 after infection. Data are mean + SE (n p 7 ). A, Percentage survival; B, mean size of primary lesion area (in square
millimeters); C, mean number of satellite lesions. , Cidofovir (1%), topical treatment; , placebo, topical treatment; , cidofovir (100 mg/kg/day),
ip treatment; , placebo, ip treatment. *P ! .05; **P ! .01; ***P ! .001.

days (P ! .05), compared with 16.3  2.9 days for the placebotreated group. Mice that received ip treatment every 3 days
(100 mg/kg/day), through day 20, lived 21.4  6.7 days (P !
.05), compared with 15.3  2.7 days for the respective placebotreated group. The combination of cidofovir cream plus parenteral drug treatment increased survival to 28.3  5.7 days
(P ! .001). On day 17 after infection, mice receiving combination treatment, cidofovir cream alone, and placebo cream
had scores for primary lesion area (SE) of 9.6  2.7 (P !
.001), 10.0  3.5 (P ! .001), and 34.2  3.7 mm2, respectively.
For these groups, the numbers of satellite lesions (SE) on
day 17 were 4.4  1.1 (P ! .01), 8.0  1.7, and 14.7  3.4 lesions, respectively. The difference in numbers of satellite lesions between the combination-treated group and the cidofovir
cream–treated group was not statistically significant. Thus, the

combination treatment was judged to be no better than topical
treatment alone in reducing the severity of primary lesions and
the numbers of satellite lesions, but the impact on mortality
was definitely superior with the combination treatment.
Less-frequent topical cidofovir treatments. In the previous
studies, we arbitrarily chose to administer topical cidofovir
treatments twice daily. Cidofovir is known to have a long intracellular half-life [22]; thus, fewer treatments per day also
may be beneficial. A study was initiated to evaluate the efficacy
of 1%-cidofovir cream given once daily, once every other day,
or once every 3 days, starting 5 days after infection (table 1).
Daily treatment resulted in the largest effect on survival and
the best reduction of primary lesion area. Treatment every other
day was not as effective for survival but did significantly reduce
primary lesion area, compared with results for the respective
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Table 1. Treatment of vaccinia virus–induced cutaneous infections, with less frequently applied cidofovir cream, in immunosuppressed hairless mice.

a

Treatment regimen

Mice that
survived, no.
(n p 8)

Time to death,
mean  SD, daysb

Primary lesion area,
c
mean  SD, mm2

Satellite lesions,
c
mean  SD, no.

0
1

20.4  2.1d
16.9  2.6

18.6  5.6e
45.4  5.4

12.4  3.6
10.0  2.4

0
0

18.8  1.8
17.0  2.9

25.7  5.6e
63.4  9.4

20.0  1.9
16.8  1.8

0
0

18.6  2.2
15.6  2.8

36.6  5.9
36.7  3.2

12.2  1.8
8.0  2.0

Days 5–14
Cidofovir (1%)
Placebo
Days 5, 7, 9, 11, and 13
Cidofovir (1%)
Placebo
Days 5, 8, 11, and 14
Cidofovir (1%)
Placebo
a
b
c
d
e

Topical treatments were given once a day on the indicated days after infection.
Data are for mice that died before day 25 after infection.
Data are as determined on day 17 after infection.
P ! .05.
P ! .01.

placebo-treated group. Treatment every 3 days delayed death
by 3 days (although the results were not statistically significant)
but did not reduce primary lesion areas. In this experiment,
none of the treatments reduced the number of satellite lesions
per mouse.
Toxicity of topical cidofovir treatment and cyclophosphamide. Topical treatments proved to be safe in terms of not
inducing weight loss during treatments. The 3%-cidofovir formulation caused skin irritation (reddening), which was more
pronounced in the shoulder region than on the hip. The twicedaily application caused a buildup of the dried cream on the
skin, which was more noticeable in the 3% cidofovir–treated
group than in the 1% cidofovir–treated group but was not
noticeable in the placebo-treated group. For this reason, the
majority of the studies were conducted with the 1%-cidofovir
formulation. A dose-response study that included a 0.5%-cidofovir formulation indicated that this dose was not as effective in
treating vaccinia lesions as was the 1%-cidofovir formulation
(data not shown). Administration of ip treatments every 3 days
had previously been shown to be nontoxic to mice [3]. Cyclophosphamide was administered to uninfected hairless mice every
4 days for 45 days, without evidence of toxic effects. The mice
gained weight over that time period and appeared to be healthy.
DISCUSSION
The results demonstrate the utility of a new immunosuppressedmouse model for the quantitative study of the progression of
vaccinia virus cutaneous lesions, satellite-lesion formation, and
mortality. Infection began with rapid development of virus titers in skin and was followed within days by virus replication
in the snout and lungs, which led to dissemination to other
vital organs and the brain. An important finding was that topically applied cidofovir treatment was superior to parenteral
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cidofovir treatment in terms of inhibiting the size of primary
cutaneous lesions and reducing the number of satellite lesions.
These results were explained by the fact that virus titers in skin
lesions were markedly reduced (1000-fold) by topical treatment
but were reduced !10-fold by parenteral treatment. Because
topical treatment reduced virus titers in the primary lesions,
we believe that this treatment also markedly reduced virus titers
in the snout. Transmission of virus from primary lesion to snout
most likely occurred, since the placebo-treated mice were observed to bite and scratch lesions in the hip area.
The best efficacy was observed when topical treatments were
initiated 1 day after infection, and efficacy decreased when
treatments started on day 3 or 5 after infection. Topical treatments started as late as 9 days after infection delayed the time
to death but did not help resolve preexisting lesions. Parenteral
treatments also delayed the time to death, relative to that in
the placebo-treated groups. Since the treatment regimens used
were different (twice daily for 7 days for topical treatment vs.
every 3 days, through day 21, for parenteral treatment), direct
comparisons of the efficacy of the 2 treatments, in terms of
prevention of death, may not be warranted. During the experiments, topical treatments were terminated well before parenteral treatments. It has been reported that human patients
with molluscum contagiosum infection had detectable levels of
cidofovir in their blood and excreted in their urine [21]. In
particular, wounded skin or skin with viral lesions may permit
internalization of drug. Topical cidofovir treatment was highly
likely to have introduced some drug systemically in the mouse
model, which provided protection against internal infection.
In the first week of vaccinia virus infection in immunosuppressed hairless mice, the majority of the virus burden was in
the skin. Thus, severely reducing that virus burden by topical
treatment slowed disease progression and may have helped the

mice live longer. Parenteral treatment was not effective in reducing the virus burden in the skin. It seems logical that topical
treatment of vaccinia complications in humans would be similarly more effective than parenteral treatment, owing to a concentration effect. The drug has already been used to topically
treat molluscum contagiosum and orf virus infections [21, 23].
More-serious infections that become systemic may be treated
by a combination of topical and parenteral routes, as was demonstrated in one of the present experiments. Treatment with
VIG combined with an antiviral drug also may be more effective, as has been previously reported for mice [18]. A single
case of progressive vaccinia in a patient with chronic lymphocytic leukemia was treated with the combination of VIG and
ribavirin [24], and the patient’s condition improved. However,
conclusions regarding the efficacy of this combination therapy
cannot be drawn from the results for a single case. In the future,
information on the use of an antiviral agent combined with
VIG may be obtained by use of our experimental immunosuppressed-mouse model.
The mice used in the present study were not adversely affected by topical treatment with 1%-cidofovir cream. Treatment
with 3%-cidofovir cream caused skin reddening and crusting
of the material on the skin. This also was evident during treatment of molluscum contagiosum infection in humans [21].
The 1%-cidofovir formulation appeared to be well tolerated by
the mice. Topical treatments may not necessarily be safe for
humans, because of potential of the drug to cause kidney damage [25] and because the drug has been shown to be absorbed
into the body by the topical route [21].
The application of a topically applied antiviral agent may
not be practical for severe smallpox and monkeypox virus infections, because the lesions are distributed over the entire body.
Perhaps more importantly, lesions also may be distributed internally throughout the oropharynx and alimentary canal. However, topical treatment should definitely be considered for localized infections, particularly for those complications arising
from smallpox vaccination. The new animal model reported
here may provide insights into the impact of compounds or
combinations of compounds on these infections.
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